Disease-modifying therapies and infectious risks in multiple sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Disease-modifying therapies and infectious risks in multiple sclerosis

Published:2016-03-04 Issue:4 Volume:12 Page:217-233
ISSN:1759-4758
Container-title:Nature Reviews Neurology
language:en
Short-container-title:Nat Rev Neurol

Author:

Winkelmann Alexander,Loebermann Micha,Reisinger Emil C.,Hartung Hans-Peter,Zettl Uwe K.

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Clinical Neurology

Link

http://www.nature.com/articles/nrneurol.2016.21.pdf

Reference255 articles.

1. Lassmann, H. Pathology and disease mechanisms in different stages of multiple sclerosis. J. Neurol. Sci. 333, 1–4 (2013).

2. Lucchinetti, C. F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188–2197 (2011).

3. Mahad, D. H., Trapp, B. D. & Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14, 183–193 (2015).

4. Lassmann, H. Spinal cord pathology in multiple sclerosis. Lancet Neurol. 14, 348–349 (2015).

5. Zettl, U. K., Stuve, O. & Patejdl, R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun. Rev. 11, 167–173 (2012).

Cited by 202 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study;Multiple Sclerosis and Related Disorders;2024-10

2. Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study;Multiple Sclerosis and Related Disorders;2024-10

3. Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review;Journal of Neurology;2024-09-12

4. Data-driven risk/benefit estimator for multiple sclerosis therapies;2024-08-17

5. Low-dose rituximab regimen does not increase severe COVID-19 risk in patients with neuroimmune diseases during the pandemic: a cross-sectional study;2024-07-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3